WO2008042941A3 - Anticors anti-ephb4 humains et leur utilisation dans le traitement de l'oncologie et de maladies liées a la vasculogenèse - Google Patents
Anticors anti-ephb4 humains et leur utilisation dans le traitement de l'oncologie et de maladies liées a la vasculogenèse Download PDFInfo
- Publication number
- WO2008042941A3 WO2008042941A3 PCT/US2007/080270 US2007080270W WO2008042941A3 WO 2008042941 A3 WO2008042941 A3 WO 2008042941A3 US 2007080270 W US2007080270 W US 2007080270W WO 2008042941 A3 WO2008042941 A3 WO 2008042941A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vasculogenesis
- treatment
- oncology
- related disease
- humanized anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des versions humaines d'anticorps monoclonaux de souris anti-EphB4. L'invention concerne également des compositions pharmaceutiques, des compositions immunothérapeutiques et des procédés d'utilisation d'anticorps thérapeutiques qui se lient à l'antigène humain EphB4 et qui peuvent médier ADCC, CDC, et/ou l'apoptose du traitement de tumeurs malignes humaines et de pathologies et de maladies liées à la vasculogenèse.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82819006P | 2006-10-04 | 2006-10-04 | |
US60/828,190 | 2006-10-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008042941A2 WO2008042941A2 (fr) | 2008-04-10 |
WO2008042941A3 true WO2008042941A3 (fr) | 2008-12-11 |
Family
ID=39269178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/080270 WO2008042941A2 (fr) | 2006-10-04 | 2007-10-03 | Anticors anti-ephb4 humains et leur utilisation dans le traitement de l'oncologie et de maladies liées a la vasculogenèse |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008042941A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008112290A2 (fr) * | 2007-03-12 | 2008-09-18 | Vasgene Therapeutics, Inc. | Utilisation du récepteur ephb4 comme marqueur diagnostique et cible thérapeutique dans le cancer de l'ovaire |
AU2008287427B2 (en) * | 2007-08-13 | 2014-10-09 | Vasgene Therapeutics, Inc. | Cancer treatment using humanized antibodies that bind to EphB4 |
JP5808349B2 (ja) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | セラノーシスのためのバイオマーカー |
JP2013526852A (ja) | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 疾患に対する循環バイオマーカー |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6719971B1 (en) * | 1991-06-14 | 2004-04-13 | Genentech, Inc. | Method for making humanized antibodies |
US20050249736A1 (en) * | 2003-03-12 | 2005-11-10 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
-
2007
- 2007-10-03 WO PCT/US2007/080270 patent/WO2008042941A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6719971B1 (en) * | 1991-06-14 | 2004-04-13 | Genentech, Inc. | Method for making humanized antibodies |
US20050249736A1 (en) * | 2003-03-12 | 2005-11-10 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
Also Published As
Publication number | Publication date |
---|---|
WO2008042941A2 (fr) | 2008-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301196I2 (nl) | inebilizumab | |
WO2006089133A3 (fr) | Anticorps anti-cd19 et leur utilisation en oncologie | |
TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
WO2006121852A3 (fr) | Traitements des maladies auto-immunes par anticorps anti-cd19 | |
WO2005103081A3 (fr) | Anticorps monoclonaux humains diriges contre cd20 | |
WO2006099875A8 (fr) | Anticorps diriges contre cd38 pour le traitement du myelome multiple | |
MY149630A (en) | Antibodies against amyloid-beta peptide | |
TN2010000210A1 (en) | Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same | |
MX355181B (es) | Anticuerpos humanos contra el factor tisular. | |
UA90457C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms | |
MX2009013656A (es) | Composiciones terapeuticas anti-cd20 y metodos. | |
MY155603A (en) | Notch-binding agents and antagonists and methods of use thereof | |
MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
CY1115572T1 (el) | Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου | |
WO2008066691A3 (fr) | Tes7, et anticorps se liant à celui-ci | |
WO2008105886A3 (fr) | Anticorps spécifiques fcgriib humanisés, et leurs procédés d'utilisation | |
WO2005110474A3 (fr) | ANTICORPS SPÉCIFIQUES FcϜRIIB HUMANISÉS ET MÉTHODES D’UTILISATION | |
UA89350C2 (uk) | Гуманізоване антитіло, що зв'язує людський cd20 | |
AR062840A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2) | |
WO2008100563A3 (fr) | Compositions et méthodes pour diagnostiquer et traiter le cancer | |
WO2008042941A3 (fr) | Anticors anti-ephb4 humains et leur utilisation dans le traitement de l'oncologie et de maladies liées a la vasculogenèse | |
WO2008152537A3 (fr) | Anticorps monoclonaux humanisés dirigés contre le récepteur du facteur de croissance épidermique humain, leur utilisation, et procédé correspondant | |
CY1116887T1 (el) | Anti-cd19 αντισωματα και χρησεις στην ογκολογια | |
UA108207C2 (xx) | Високоафінне людське антитіло до людського ангіопоетину-2 | |
UA102085C2 (ru) | ВЫДЕЛЕННОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С hGM-CSF, И КОМПОЗИЦИЯ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07868359 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07868359 Country of ref document: EP Kind code of ref document: A2 |